Sotagliflozin reduces adverse cardiovascular events

Nat Rev Cardiol. 2021 Feb;18(2):74. doi: 10.1038/s41569-020-00486-0.
No abstract available

Publication types

  • Comment

MeSH terms

  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / prevention & control
  • Glycosides
  • Humans
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

  • Glycosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol